Tag: Gastroenterology

ENTRETIEN AVEC CARMELA GUGLIOTTA, Laborgemeinschaft 1, Zurich

fCAL® turbo de BÜHLMANN Santé Canada Licence: 96808 English Version ENTRETIEN AVEC CARMELA GUGLIOTTA, Laborgemeinschaft 1, Zurich Vous avez dernièrement choisi d’utiliser le nouveau test fCAL® turbo de BÜHLMANN® turbo sur votre Cobas® c501 de Roche. Pourriez-vous nous indiquer les raisons de votre choix ? Nos clients nous ont demandé s’il était possible que notre laboratoire
Continue Reading

Safe Use of Stool Extracts on Clinical Chemistry Analyzers

BÜHLMANN fCAL® turbo is for Research Use Only. Not to be used in diagnostic procedures. Health Canada License: 96808 BÜHLMANN fCAL® turbo Stool extracts used in the BÜHLMANN fCAL® turbo on clinical chemistry analyzers can be applied without any concern of system contamination. BÜHLMANN investigated this new sample matrix with the goal to exclude potential risks.
Continue Reading

A Novel Turbidimetric Immunoassay for Fecal Calprotectin Optimized for Routine Chemistry Analyzers

BÜHLMANN fCAL® turbo Citation: Nilsen, T. et. al.  A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2016 Sep 15. PMID:27629827 The publication describes the technical performance of the turbidimetric assay on the cobas c501 and the Mindray BS-380. Highlight from this Publication Short assay time of 10 min with
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725. “Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.” Learn More
Continue Reading

Comparison of Three Tests for Faecal Calprotectin in Children and Young Aults: a Retrospective Monocentric Study

BÜHLMANN fCAL® ELISA Citation Prell, C, Nagel D, Freudenberg H, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study, BMJ Open. 2014;4:e004558 doi:10.1136/bmjopen-2013-004558. “In conclusion, measurement of FC in paediatric patients with unspecific symptoms is very helpful in order to avoid invasive procedure.” Highlights from this Publication “In conclusion, measurement
Continue Reading

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

BÜHLMANN fCAL® ELISA Citation Seenan, JP,Thomson,Rankin K,Smith K, Gaya DR.Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology.  2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467. “we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.” Learn More
Continue Reading

Fecal Calprotectin in Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood.  Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi:  10.2147/CEG.S51902 “The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features
Continue Reading

Diagnostic Accuracy and Clinical Application of Faecal Calprotectin in Adult Patients Presenting with Gastrointestinal Symptoms in Primary Care

BÜHLMANN fCAL® ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771. “This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA] testing in primary care…..to be
Continue Reading

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. “We found FC to be a very accurate
Continue Reading

Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis

BÜHLMANN fCAL® ELISA Citation Theede, K. ,Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis, Inflamm Bowel Dis. 2016 May;22(5):1042-8. doi: 10.1097/MIB.0000000000000736. “…our histological inflammatory activity score is closely related to the concentration of FC and thereby has the advantage that the presence of
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,